{
    "clinical_study": {
        "@rank": "65557", 
        "arm_group": [
            {
                "arm_group_label": "Postoperative Chemo WITH Zaltrap", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer).  Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles.  After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection.  At the time of resection, the tumor will be collected for biomarker discovery.\nFollowing resection, patients will receive chemotherapy with zaltrap for 3 additional months.  Patients may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months."
            }, 
            {
                "arm_group_label": "Postoperative chemo WITHOUT zaltrap", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer).  Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles.  After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection.  At the time of resection, the tumor will be collected for biomarker discovery.\nFollowing resection, patients will receive chemotherapy (without zaltrap) for 3 additional months."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the safety of Zaltrap in patients who undergo\n      pre-operative chemotherapy with Zaltrap. The investigators hypothesize that Zaltrap my\n      impact colorectal cancer growth and metastasis."
        }, 
        "brief_title": "Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer", 
        "completion_date": {
            "#text": "February 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adenocarcinoma of the Colon", 
            "Adenocarcinoma of the Rectum"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Colorectal Neoplasms", 
                "Rectal Neoplasms", 
                "Colonic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Eligible patients will receive 3 months of chemotherapy consisting of either FOLFOX or\n      FOLFIRI (in the case of liver limited CRC) or FOLFOX (in the case of rectal cancer).  The\n      FOLFOX regimen consists of Oxaliplatin, Leucovorin, and 5-FU. The FOLFIRI regimen consists\n      of Irinotecan, Leucovorin, and 5-FU.  Zaltrap will be administered with chemotherapy every 2\n      weeks for the first 5 out of 6 planned treatment cycles.  After a standard 3-4 week recovery\n      period (i.e. 5-6 week's from the last Zaltrap dose), patients will undergo standard\n      resection.  At the time of resection, the tumor will be collected for biomarker discovery.\n\n      Following resection, patients will be randomly assigned (1:1) to receive chemotherapy with\n      or without zaltrap for 3 additional months.  Patients assigned to Zaltrap may continue\n      zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months.\n      Patients will have research blood draws periodically both in the preoperative and\n      postoperative period.\n\n      The investigators plan to demonstrate that pre-operative chemotherapy with Zaltrap is not\n      associated with any safety signals that would preclude further drug development in this\n      patient population.   The investigators also plan to perform correlative studies to identify\n      potential biomarkers for Zaltrap activity.\n\n      The investigators hypothesize that antiangiogenic therapy may specifically target the\n      micrometastatis niche of patients with liver limited metastatic colorectal cancer to\n      significantly increase the chance of cure for these patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have pathologically confirmed adenocarcinoma of the colon or rectum.\n\n          -  In patients with liver-limited metastatic colorectal cancer, a curative approach is\n             indicated following evaluation by hepatobiliary surgeon as part of multidisciplinary\n             management. Select patients requiring two stage procedure are also eligible following\n             evaluation by hepatobiliary surgeon as part of multidisciplinary management.\n\n          -  In patients with rectal cancer, primary tumor that is clinically T3-4 or N +\n             (evaluation by colorectal surgery is required as part of multidisciplinary approach).\n\n          -  No prior chemotherapy for metastatic disease is allowed for patients with CRC-liver\n             mets. (adjuvant FOLFOX is permitted)\n\n          -  No prior chemotherapy for proximal rectal cancer is allowed\n\n          -  ECOG Performance status \u2264 2.\n\n          -  Age >18 years old.\n\n          -  Patients must have adequate bone marrow, kidney, and liver function as assessed by\n             laboratory parameters.\n\n               1. WBC                 \u2265  3,000/uL\n\n               2. Total Bilirubin   \u2264 1.5 x upper limits of normal\n\n               3. AST (SGOT)         \u2264 3 x upper limits of normal\n\n               4. ALT (SGPT)         \u2264 3  x upper limits of normal\n\n               5. Hemoglobin            \u2265 9.0 g/dl (without transfusion within 7 d)\n\n               6. ANC                         \u2265 1500 /ml\n\n               7. Platelets             \u2265100 K/ml (without transfusion)\n\n               8. Calculated CrCL    > 50 ml/min\n\n          -  Ability to understand and the willingness to sign a written informed consent\n             document.\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study entry and\n             for the duration of study participation.\n\n        Exclusion Criteria:\n\n          -  Patients with untreated CNS metastases.\n\n          -  Significant medical co-morbidity that would preclude safe administration of cytotoxic\n             therapy, including but not limited to:\n\n               1. Cardiovascular disease\n\n                    1. Unstable angina\n\n                    2. Myocardial infarction/ CABG < 3 months prior to study initiation\n\n                    3. Untreated coronary artery disease\n\n                    4. NYHA class III or IV heart failure\n\n               2. Ongoing serious infection\n\n                    1. Bacteremia or sepsis requiring intravenous antibiotics\n\n                    2. HIV with AIDS defining illness\n\n               3. Inadequate oral nutritional intake: Requirement for daily intravenous fluids or\n                  total parenteral nutrition.\n\n               4. Neurological: Stroke \u2264 6 months\n\n               5. Psychiatric illness/social situations that would limit compliance with study\n                  requirement\n\n          -  Patients may not receive another investigational agent.\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to Ziv-aflibercept.\n\n          -  Pregnant (positive pregnancy test) and lactating women are excluded from the study\n             because the risks to an unborn fetus or potential risks in nursing infants are\n             unknown.\n\n          -  Major surgical procedure \u2264 4 weeks from starting therapy.\n\n          -  Grade 3-4 hemorrhage, erosive esophagitis or gastritis, infectious or inflammatory\n             bowel disease, or diverticulits \u2264 3 months from starting therapy.\n\n          -  Patients with known DPD deficiency\n\n          -  Patients with known Gilbert's syndrome\n\n          -  Patients with \u2265 2g/24 hour urine protein.  If urine protein on random UA is \u2264 300\n             mg/dl, a 24 hour urine protein is not required.\n\n          -  Symptomatic peripheral sensory neuropathy grade  \u2265 2.\n\n          -  Other malignancy within the last 5 years from study entry, except for basal /squamous\n             cell skin cancer, in situ cervical cancer, or non-metastatic prostate cancer."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046538", 
            "org_study_id": "1309014302", 
            "secondary_id": "2012-AFL-18"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Postoperative Chemo WITH Zaltrap", 
                    "Postoperative chemo WITHOUT zaltrap"
                ], 
                "description": "400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)", 
                "intervention_name": "Leucovorin", 
                "intervention_type": "Drug", 
                "other_name": "Wellcovorin"
            }, 
            {
                "arm_group_label": [
                    "Postoperative Chemo WITH Zaltrap", 
                    "Postoperative chemo WITHOUT zaltrap"
                ], 
                "description": "85 mg/m2 IV over two hours", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug", 
                "other_name": "Eloxatin"
            }, 
            {
                "arm_group_label": [
                    "Postoperative Chemo WITH Zaltrap", 
                    "Postoperative chemo WITHOUT zaltrap"
                ], 
                "description": "400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours", 
                "intervention_name": "5-FU", 
                "intervention_type": "Drug", 
                "other_name": "Adrucil, fluorouracil"
            }, 
            {
                "arm_group_label": [
                    "Postoperative Chemo WITH Zaltrap", 
                    "Postoperative chemo WITHOUT zaltrap"
                ], 
                "description": "180 mg/m2 IV over 90 minutes", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug", 
                "other_name": "Camptosar"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Levoleucovorin", 
                "Oxaliplatin", 
                "Irinotecan"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 24, 2014", 
        "location": {
            "contact": {
                "email": "alm2051@med.cornell.edu", 
                "last_name": "Alice Mercado, RN", 
                "phone": "212-746-5430"
            }, 
            "facility": {
                "address": {
                    "city": "New York city", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Weill Cornell Medical College"
            }, 
            "investigator": {
                "last_name": "Manish Shah, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Preoperative Chemotherapy With Ziv-aflibercept (Zaltrap) Followed by Postoperative Chemotherapy With or Without Ziv-aflibercept (Zaltrap) in Patients With Advanced Resectable Colorectal Cancer", 
        "overall_contact": {
            "email": "alm2051@med.cornell.edu", 
            "last_name": "Alice Mercado, RN", 
            "phone": "212-746-5430"
        }, 
        "overall_official": {
            "affiliation": "Weill Medical College of Cornell University", 
            "last_name": "Manish A. Shah, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Data and Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Capture the number of adverse events experienced by advanced resectable colorectal cancer subjects treated with pre-operative chemotherapy and Zaltrap", 
                "measure": "Number of adverse events experienced", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 24 months per patient"
            }, 
            {
                "description": "Capture the number of subjects who demonstrate an improvement (response) in colorectal cancer status after being treated with pre-operative chemotherapy and zaltrap.", 
                "measure": "Number of subjects who demonstrate a response to pre-operative chemotherapy and zaltrap", 
                "safety_issue": "No", 
                "time_frame": "Approximately 24 months per patient"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046538"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Calculate rate of progression-free survival for subjects following treatment chemotherapy and Zaltrap", 
            "measure": "Survival duration without disease progression", 
            "safety_issue": "No", 
            "time_frame": "2 years per patient"
        }, 
        "source": "Weill Medical College of Cornell University", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Weill Medical College of Cornell University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}